- A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer
-
Wilson MK, Mercieca-Bebber R, Friedlander M
- KMID: 2417469
- J Gynecol Oncol.
- 2018 Sep;29(5):e81.
- doi: 10.3802/jgo.2018.29.e81
Health related quality of life (HRQOL) is a key priority for patients with ovarian cancer as there is significant morbidity associated with the disease and the treatment. It is therefore... -
- CITED
-
- Close
- SHARE
-
- Close
- Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
-
Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield , Grant P, Kichenadasse G, Vaughan M, Brand A, Shannon C, Gebski V, Stockler M, Friedlander M
- KMID: 2177878
- J Gynecol Oncol.
- 2013 Oct;24(4):359-366.
- doi: 10.3802/jgo.2013.24.4.359
OBJECTIVE: Intraperitoneal (IP) chemotherapy in women with optimally debulked stage III ovarian cancer has been reported to prolong overall survival, but has not been widely adopted due to concerns about... -
- CITED
-
- Close
- SHARE
-
- Close
- PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
-
Kok PS, Beale P, O'Connell , Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M, on behalf of the PARAGON Investigators
- KMID: 2457159
- J Gynecol Oncol.
- 2019 Sep;30(5):e86.
- doi: 10.3802/jgo.2019.30.e86
OBJECTIVE: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON... -
- CITED
-
- Close
- SHARE
-
- Close
